Celularity Inc. to Host Investor and Analyst Research & Development Day

In This Article:

Event Will Be Hosted On-site and Aired Virtually Highlighting Research, Clinical and Commercial Progress

FLORHAM PARK, N.J., April 22, 2024 (GLOBE NEWSWIRE) --   Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today it will host an on-site and virtual Investor and Analyst Research & Development (R&D) Day. The Investor and R&D Day, scheduled for Tuesday, May 21, 2024, from 12:00 p.m. to 4:00 p.m. ET in Florham Park, NJ, will showcase progress and advancements of Celularity’s placental technology platform and clinical development pipeline and future growth expectations for its commercial advanced biomaterials business. The event will feature members of Celularity’s executive management team, including:

Celularity Executive Management:

  • Robert J. Hariri, M.D., Ph.D., - Celularity Chairman, CEO and Founder

  • Stephen Brigido, DPM - President, Degenerative Diseases

  • Adrian Kilcoyne M.D., M.P.H., M.B.A.- Chief Medical Officer

  • Ramji Krishnan, Ph.D.-Chief Technology Officer

A live webcast of the Investor and Analyst R&D Day can be accessed by visiting the Investor Relations section of Celularity's website at www.celularity.com. A replay will also be available for 30 days following the event. An invited panel of expert medical speakers will provide insights into the technology and programs as well.

“We are very excited to host our first on-site and virtual Investor and Analyst R&D Day at our world-class headquarters, research, and manufacturing center. We will showcase the capabilities resident at Celularity and share the progress made in our development programs and commercial business. Our unique bifurcated regenerative and cellular medicine business model, which leverages both clinical and commercial stage technologies, will be presented and toured during the day,” added Celularity CEO and Founder. Dr. Robert J. Hariri.

About Celularity
Celularity Inc. (NASDAQ: CELU) is an innovative regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. What sets Celularity apart is its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Celularity's unique approach, harnessing the placenta’s biology and ready availability, is paving the way for therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.